Next -generation probiotics as potential therapeutic supplement for gastrointestinal infections

Nidhi Gupta , Kajal Kachhawaha , Deepak Kumar Behera , Vijay Kumar Verma
{"title":"Next -generation probiotics as potential therapeutic supplement for gastrointestinal infections","authors":"Nidhi Gupta ,&nbsp;Kajal Kachhawaha ,&nbsp;Deepak Kumar Behera ,&nbsp;Vijay Kumar Verma","doi":"10.1016/j.prerep.2024.100002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The experimental evolution of gut microbiota<span><span> and human wellness<span><span> has witnessed increased recognition in the past decade. In the human gastrointestinal tract<span>, about 100 million bacteria, viruses, and fungi exist that play a symbiotic relationship with human immunity. Simultaneously, the rising concerns and consequences of antimicrobial and </span></span>antibiotic resistance are shrinking new antibiotic discoveries and demanding alternative approaches for eradicating infectious diseases. The next-generation </span></span>probiotics (NGPs) could be a potential answer to this global challenge.</span></div></div><div><h3>Methods</h3><div><span><span>Recognizing the limitations of traditional probiotics in terms of diversity and scope, the study explored the broader applications of NGPs and their potential to address various gut health issues, </span>dysbiosis<span><span>, and gastrointestinal disorders. Here, we have strengthened the connections between the </span>gut microbiome and overall health, specifically focusing on </span></span><span><em>Helicobacter pylori</em></span> (<em>H. pylori</em><span><span>) infection and inflammatory bowel disease<span> (IBD). Using a narrative approach, the strengths and weaknesses of currently available therapies and </span></span>fecal microbiota transplantation (FMT) have been described.</span></div></div><div><h3>Results and discussion</h3><div>The outcome of this study reveals the promising potential of NGPs in offering targeted interventions that overcome the limitations of existing approaches. We highlight the perspective of NGPs by addressing the benefits, with their anti-inflammatory properties and ability to enhance gut health. However, we also acknowledge crucial gaps in current knowledge in the field of NGPs’ treatment, particularly the limited clinical evidence for their efficacy etc.</div></div>","PeriodicalId":101015,"journal":{"name":"Pharmacological Research - Reports","volume":"1 ","pages":"Article 100002"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Research - Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950200424000028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The experimental evolution of gut microbiota and human wellness has witnessed increased recognition in the past decade. In the human gastrointestinal tract, about 100 million bacteria, viruses, and fungi exist that play a symbiotic relationship with human immunity. Simultaneously, the rising concerns and consequences of antimicrobial and antibiotic resistance are shrinking new antibiotic discoveries and demanding alternative approaches for eradicating infectious diseases. The next-generation probiotics (NGPs) could be a potential answer to this global challenge.

Methods

Recognizing the limitations of traditional probiotics in terms of diversity and scope, the study explored the broader applications of NGPs and their potential to address various gut health issues, dysbiosis, and gastrointestinal disorders. Here, we have strengthened the connections between the gut microbiome and overall health, specifically focusing on Helicobacter pylori (H. pylori) infection and inflammatory bowel disease (IBD). Using a narrative approach, the strengths and weaknesses of currently available therapies and fecal microbiota transplantation (FMT) have been described.

Results and discussion

The outcome of this study reveals the promising potential of NGPs in offering targeted interventions that overcome the limitations of existing approaches. We highlight the perspective of NGPs by addressing the benefits, with their anti-inflammatory properties and ability to enhance gut health. However, we also acknowledge crucial gaps in current knowledge in the field of NGPs’ treatment, particularly the limited clinical evidence for their efficacy etc.
新一代益生菌作为潜在的胃肠道感染治疗补充剂
在过去的十年中,肠道微生物群和人类健康的实验进化得到了越来越多的认识。在人类的胃肠道中,存在着大约1亿个细菌、病毒和真菌,它们与人体的免疫系统有着共生关系。与此同时,对抗菌素和抗生素耐药性的日益关注和后果正在减少新的抗生素发现,并要求采用其他方法根除传染病。下一代益生菌(NGPs)可能是应对这一全球挑战的潜在答案。方法认识到传统益生菌在多样性和范围上的局限性,本研究探索了ngp的更广泛应用及其在解决各种肠道健康问题、生态失调和胃肠道疾病方面的潜力。在这里,我们加强了肠道微生物群与整体健康之间的联系,特别关注幽门螺杆菌(H. pylori)感染和炎症性肠病(IBD)。使用叙述的方法,目前可用的治疗和粪便微生物群移植(FMT)的优点和缺点进行了描述。结果和讨论本研究的结果揭示了ngp在提供有针对性的干预措施方面的巨大潜力,这些干预措施克服了现有方法的局限性。我们通过解决ngp的益处,以及它们的抗炎特性和增强肠道健康的能力来强调ngp的观点。然而,我们也承认目前在ngp治疗领域的知识存在重大差距,特别是其疗效的临床证据有限等。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信